A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs M 3541 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors EMD Serono Research & Development Institute
- 01 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 20 May 2019 Planned End Date changed from 31 Dec 2019 to 13 Aug 2020.
- 20 May 2019 Planned primary completion date changed from 3 Jul 2019 to 18 Nov 2019.